KILITCH — Kilitch Drugs (India) Share Price
0.000.00%
Last trade - 00:00- IN₹5.80bn
- IN₹5.42bn
- IN₹1.54bn
- 57
- 22
- 70
- 47
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 25.21 | ||
| PEG Ratio (f) | 1.11 | ||
| EPS Growth (f) | 29.43% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.92 | ||
| Price to Tang. Book | 3.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.34 | ||
| EV to EBITDA | 19.75 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.83% | ||
| Return on Equity | 8.91% | ||
| Operating Margin | 13.48% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 533.2 | 685.23 | 1,142.34 | 1,395.99 | 1,543.72 | 2,220 | 2,940 | 13.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -79.08 | +334.33 | +122.41 | +37.39 | +26.56 | +29.77 | +28.57 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kilitch Drugs (India) Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in developing, manufacturing and marketing a range of pharmaceutical formulations. The Company’s products include Parenteral and Nasal Products, Oral, Effervescent, Nutritional Products, Medical Devices, and Cosmetics and Herbal Products. Its Parenteral and Nasal Products has a range of products that help in gastroenterology, anti-inflammatory, anti-malaria, diagnostic, uterine stimulants, veterinary and other areas in the form of ampoules and vials. Its range of oral formulations includes tablets, capsules, dry syrups and oral powders. It provides a range of cosmetics ranging from oil, lotion, liquid to cream and paste in the skin care, personal care and hair care categories. Its herbal products are useful for sore throat, prostate problems, and can be used as supplements for diabetes, obesity, libido and others. Its medical devices offer a C-Seal brand.
Directors
- Sunil Jain CFO (37)
- Princy Asati CCO (26)
- Mukund Mehta MDR (57)
- Bhavin Mehta EDR (35)
- Mira Mehta EDR
- Neelima Waingankar EDR (43)
- Murti Krishna NED (66)
- Hemang Engineer NID (47)
- Venkita Rajan NID (75)
- Last Annual
- March 31st, 2024
- Last Interim
- March 31st, 2024
- Incorporated
- May 12th, 1992
- Public Since
- February 14th, 1994
- No. of Employees
- 153
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 16,082,319
- Address
- Village: Savroli, MUMBAI, 400088
- Web
- https://www.kilitch.com/
- Phone
- +91 2261214100
- Contact
- Pushpa Nyoupane
- Auditors
- Suryaprakash Maurya & Co
Upcoming Events for KILITCH
Kilitch Drugs (India) Ltd Annual Shareholders Meeting
Similar to KILITCH
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Kilitch Drugs (India) share price?
As of Today at 15:38 UTC, shares in Kilitch Drugs (India) are trading at IN₹320.25. This share price information is delayed by 15 minutes.
How has the Kilitch Drugs (India) share price performed this year?
Shares in Kilitch Drugs (India) last closed at IN₹320.25 and the price had moved by +64.06% over the past 365 days. In terms of relative price strength the Kilitch Drugs (India) share price has outperformed the S&P BSE 100 Index by +25.36% over the past year.
What are the analyst and broker recommendations for Kilitch Drugs (India)?
The overall consensus recommendation for Kilitch Drugs (India) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Kilitch Drugs (India) dividend yield?
Kilitch Drugs (India) does not currently pay a dividend.
Does Kilitch Drugs (India) pay a dividend?
Kilitch Drugs (India) does not currently pay a dividend.
When does Kilitch Drugs (India) next pay dividends?
Kilitch Drugs (India) does not currently pay a dividend.
How do I buy Kilitch Drugs (India) shares?
To buy shares in Kilitch Drugs (India) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kilitch Drugs (India)?
As of the previous close price of IN₹320.25, shares in Kilitch Drugs (India) had a market capitalisation of IN₹5.15bn.
Where are Kilitch Drugs (India) shares listed?
Here are the trading details for Kilitch Drugs (India):
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: KILITCH
What kind of share is Kilitch Drugs (India)?
Based on an overall assessment of its quality, value and momentum Kilitch Drugs (India) is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kilitch Drugs (India) share price forecast for 2024?
The analyst consensus target price for shares in Kilitch Drugs (India) is IN₹466.00. That is 45.51% above the last closing price of IN₹320.25.
Analysts covering Kilitch Drugs (India) currently have a consensus Earnings Per Share (EPS) forecast of IN₹11.90 for the next financial year.
What is the trend in the Kilitch Drugs (India) share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kilitch Drugs (India). Over the past six months, its share price has underperformed the S&P BSE 100 Index by -22.35%.
As of the last closing price of IN₹320.25, shares in Kilitch Drugs (India) were trading -5.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kilitch Drugs (India) PE Ratio?
The Kilitch Drugs (India) PE ratio based on its reported earnings over the past 12 months is 25.21. The shares last closed at IN₹320.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kilitch Drugs (India)?
Kilitch Drugs (India)'s management team is headed by:
- Sunil Jain - CFO
- Princy Asati - CCO
- Mukund Mehta - MDR
- Bhavin Mehta - EDR
- Mira Mehta - EDR
- Neelima Waingankar - EDR
- Murti Krishna - NED
- Hemang Engineer - NID
- Venkita Rajan - NID